ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

ACS President Lawrence Emphasizes Prevention Gains Since 1971

April 10, 1992

Medenica Granted Extension Of Privileges At Hilton Head Hospital

November 26, 1993

In Brief: XIIIth Congress Draws Record Number Of Abstracts, 3,000 Registrants So Far; Exhibit Area Sold Out

March 5, 1982

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

November 28, 2014

Clearinghouse Agrees On Three Big New Carcinogens

May 4, 1979

Citizens Committee Notes Broad Support For NCI Funds

August 24, 1979